Amicus Therapeutics Completes Merger with BioMarin, Becomes Wholly-Owned Subsidiary
Summary
Amicus Therapeutics has completed its merger with BioMarin Pharmaceutical Inc., becoming a wholly-owned subsidiary and deregistering all unsold securities.
Key Events
-
Merger Completion
Amicus Therapeutics, Inc. has completed its merger with Lynx Merger Sub 1, Inc., a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., as of April 27, 2026.
-
Becomes Wholly-Owned Subsidiary
As a result of the merger, Amicus Therapeutics is now a wholly-owned subsidiary of BioMarin Pharmaceutical Inc., marking the end of its independent public trading status.
-
Securities Deregistration
All offerings and sales of securities under previous S-3 registration statements have been terminated, and all remaining unsold securities have been removed from registration.
Analysis
This filing confirms the definitive completion of the merger between Amicus Therapeutics and BioMarin Pharmaceutical Inc. As of April 27, 2026, Amicus Therapeutics is no longer an independent, publicly traded entity, having become a wholly-owned subsidiary of BioMarin. This follows the final French regulatory clearance announced just four days prior on April 23, 2026. For existing shareholders, this marks the conclusion of their investment in Amicus as a standalone company, with their shares having been converted or acquired according to the merger terms. The deregistration of securities is a standard administrative step following such a major corporate transaction.
At the time of this filing, FOLD was trading at $14.49 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.5B. The 52-week trading range was $5.51 to $14.50. This filing was assessed with neutral market sentiment and an importance score of 10 out of 10.